Miscellaneous Ocular Agents

FDA: Vision Impairment, Other Serious Side Effects Tied to Compounded Injectable

By July 31, 2017

The triamcinolone and moxifloxacin injection was intended for use as post-op prophylaxis for ocular inflammation and endophthalmitis to eliminate the use of post-op eye drops.

Eye Exams Should Be Requirement for Infants Potentially Exposed to Zika

July 18, 2017

One in 5 of the infants had sight-threatening eye abnormalities, with optic nerve and retinal abnormalities the most common.

Early Biomarker May Help Differentiate Parkinsonism Disorders

July 12, 2017

Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.

NDA Accepted for Anti-Inflammatory Inj Post-Cataract Surgery

By June 26, 2017

Dexycu injection was developed to help compliance—especially among elderly patients—and avoid dosing errors associated with conventional treatments that depend on self-administered eye drops multiple times a day.

Can Dietary Vitamin K Protect Against Cataracts?

May 22, 2017

After adjustment for potential confounders, the risk of cataracts was lower among participants in the highest versus the lowest tertile of dietary vitamin K1 intake (hazard ratio, 0.71).

Implant Compared to Systemic Anti-inflammatory Therapy for Treating Uveitis

May 08, 2017

In seven-year follow-up, visual acuity better than with intravitreous fluocinolone acetonide implants

Novel Therapy Shows Potential in Thyroid-Associated Ophthalmopathy

May 04, 2017

The researchers found that in the intention-to-treat population, 69 and 20% of those who received teprotumumab and placebo, respectively, had a response at week 24.

Anti-VEGF Treatments Examined for Effects on Diabetic Retinopathy

April 28, 2017

Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).

Treatment Combo Shows Promise for JIA-Associated Uveitis

April 27, 2017

Children with active JIA-associated uveitis who were taking a stable dose of methotrexate were randomly assigned to either adalimumab or placebo for 2 weeks.

Novel Therapy Shows Promise in Retinitis Pigmentosa

April 25, 2017

The researchers observed an increase in cone-like cells after switching rod to cone-like photoreceptors in situ by inactivation of Nrl or Nr2e3.

FDA Approves Treatment for All Forms of Diabetic Retinopathy

By April 17, 2017

The analysis indicated that patients with and without DME in the Lucentis treatment group had improvements in the severity of their retinopathy.

Recreational 'Poppers' Linked to Blurriness and Blind Spots

April 12, 2017

The 6 products with isopropyl nitrite were associated with visual problems while the 2 without were not.

Cardio-, Cerebrovascular Safety of Ranibizumab in DME Evaluated

April 10, 2017

The researchers assessed the cardiovascular and cerebrovascular safety of ranibizumab 0.3mg and 0.5mg vs. sham with and without laser in diabetic macular edema.

Impact of Age-Related Macular Degeneration May Differ by Ethnicity

March 31, 2017

The researchers found that early AMD was associated with a small reduction in VSF compared with no AMD in adjusted models in a group of ethnic Chinese but not in groups of ethnic Indians or Malays.

Implantable Artificial Retina in the Works

By March 29, 2017

The finished product is still some way off being consumer-ready, but when complete it could restore sight to millions of people with degenerative eye diseases.

Tocilizumab Assessed for JIA-Associated Uveitis

March 17, 2017

Rapid and maintained improvement in all ocular parameters was seen with tocilizumab treatment.

Stem Cell Therapy for AMD Appears Beneficial but Risky

March 16, 2017

One report warns of severe visual loss after macular degeneration treatment in 'trial'

USPSTF: Amblyopia Screening Should Occur Before Age 5

March 01, 2017

Young children should be screened at least once for amblyopia before they turn 5 years old, according to a draft recommendation statement issued by the U.S. Preventive Services Task Force.

NDA Re-Submitted for Novel Glaucoma Drug

By February 27, 2017

Valeant have re-submitted their NDA for latanoprostene bunod ophthalmic solution after receiving a Complete Response Letter from the FDA last summer.

Dextenza NDA Resubmission Accepted for Post-Surgical Ocular Pain

By February 23, 2017

The NDA for Dextenza was resubmitted in January 2017 following a Complete Response Letter that was issued in July 2016 due to concerns with deficiencies in manufacturing processes and controls.

ADA: Diabetic Retinopathy Management Guidelines Issued

By February 22, 2017

To reduce the risk or slow the progression of of diabetic retinopathy, the guidelines recommend optimizing glycemic control, as well as lowering blood pressure and serum lipids.

More Children Suffering Ocular Burns From Detergent Pods

February 03, 2017

Young children are suffering vision-threatening burns from the chemicals inside liquid laundry detergent pods in increasing numbers, according to a research letter published online in JAMA Ophthalmology.

Exosomes Show Promise Against a Leading Cause of Blindness

January 31, 2017

Bone marrow-derived mesenchymal stem cell (BMSC)-derived exosomes promote retinal ganglion cell (RGC) survival, according to a study published online in Stem Cells Translational Medicine.

Dextenza NDA Resubmitted for Post-Surgery Ocular Pain

By January 23, 2017

Ocular has announced that it has resubmitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Dextenza (dexamethasone insert) 0.4mg, to treat ocular pain after ophthalmic surgery.

Topical Ocular Glucocorticoid Leads to Cushing's Syndrome in 9-Year-Old

January 20, 2017

In a case report published online Jan. 19 in Pediatrics, iatrogenic Cushing's syndrome (CS) is described in a 9-year-old girl who received topical ocular glucocorticoid (GC) treatment for bilateral iridocyclitis.

Macular Degeneration Drug May Reduce Number of Injections Needed

January 19, 2017

An experimental drug, AXT107, may one day make treatment simpler for patients with age-related macular degeneration, according to research published in the January 18 issue of Science Translational Medicine.

Bariatric Sx vs. Medical Tx in Progression of Diabetic Retinopathy

January 18, 2017

There are fewer cases of incident diabetic retinopathy among obese patients with type 2 diabetes undergoing bariatric surgery compared with medical treatment, according to a review and meta-analysis published online January 13 in Obesity Reviews.

Lucentis Gains Approval to Treat Myopic Choroidal Neovascularization

By January 06, 2017

Genentech announced that the Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of patients with myopic choroidal neovascularization (mCNV). This approval marks Lucentis as the first anti-vascular endothelial growth factor (VEGF) approved to treat mCNV in the United States.

Stargardt Disease Drug Candidate Receives Orphan Drug Status

By January 06, 2017

Acucela has announced that the Food and Drug Administration (FDA) has granted orphan drug designation to their candidate, emixustat (emixustat hydrochloride), for the treatment of Stargardt disease.

Links Between Preeclampsia and Later Retinal Disease Examined

December 15, 2016

Preeclampsia is associated with increased risk of maternal retinal disease, especially traction detachments, retinal breaks, and diabetic retinopathy, according to a study published in the January issue of Obstetrics & Gynecology.